TORONTO, May 24 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX-V: ARI),
announced today that Daniel B. Rubinstein, M.D., an American Board of Clinical
Oncology certified medical oncologist has joined the Company as Chief Medical
Officer.
Prior to joining ARIUS, Dr. Rubinstein served as Medical Officer at the
Center for Drug Evaluation and Research in the Division for Biological,
Therapeutic and Oncologic products in the U.S. Food and Drug Administration
(FDA). He also served as a Staff Physician at the National Cancer Institute,
NIH in Bethesda, Maryland and as an Attending Physician at the Boston
University Medical Center.
Dr. Rubinstein brings extensive research experience in the
characterization and development of therapeutic antibodies, and clinical trial
and drug regulatory experience which will be required to achieve drug
approval. Reporting to the President and Chief Scientific Officer he will be
responsible for drug development activities with the Company's clinical and
research teams, and for developing registration strategies for the Company's
compounds in the relevant markets.
"With his extensive experience in clinical oncology and expertise in the
regulatory aspects of drug development and approval, Danny is an excellent
addition to ARIUS' executive group," said Dr. David S. Young, President and
Chief Scientific Officer of ARIUS. "The hiring of Danny brings important depth
to senior personnel required to prepare for the commercialization of our
internal pipeline and to further the progress of our current technology."
Dr. Rubinstein received his medical degree and earned his bachelor's
degree in microbiology from the University of Illinois in Chicago. He is
currently a member of the American Society of Clinical Oncology, the American
Society of Hematology, the American Association for Cancer Research, and the
Massachusetts Medical Society. In addition to his role at ARIUS, Dr.
Rubinstein will maintain a clinical practice at NCI and will function as a
Scientific Consultant to Biomodifying Inc, a private biomedical company in
Miami, FL.
About ARIUS Research
ARIUS Research Inc. is a biotechnology company dedicated to personalizing
cancer therapy through the discovery and development of novel anticancer
monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
powerful MAbs targeting a variety of cancer indications. This antibody
generation engine has enabled ARIUS to assemble a growing pipeline, which is
used for commercial collaborations and in-house development. ARIUS has ongoing
partnerships with key biotechnology and drug development companies. The
company is listed on the TSX Venture Exchange under the symbol "ARI".
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
